opdivo aliv kick earn
messag net revenu quarter came slightli consensu vs
consensu although revenu fell short expect growth driven
strong opdivo yoy eliqui yoy perform non-gaap earn per
share came ahead consensu vs consensu increas
adjust earn guidanc previou guidanc
ep estim increas decreas
base reduc forecast lung market
strong opdivo growth
opdivo sale driven strong demand first quarter come around billion
quarter note opdivo revenu benefit stock
due launch mg vial accord manag approxim
 opdivo sale lung cancer indic remain
sale come varieti differ tumor opdivo experienc rapid uptak
new indic particularli adjuv melanoma exist strong enthusiasm
launch opdivo low dose yervoy renal cell carcinoma rcc addit
manag state opdivo share second-lin lung remain roughli stabl
approxim io-elig popul expect bmi share lung
remain stabl throughout compani also note modest uptak opdivo
braf mutant popul histor difficult segment popul
penetr
like caus slow overal growth increas use front-lin
lung merck keytruda plu chemotherapi base posit result
trial reduc use opdivo second-lin nsclc expect
acquir indic front-lin lung cancer may occur mid late
question remain much revenu loss nsclc may made
indic caus us rethink alreadi reduc estim see
previou note adjust opdivo note
outsid execut remain strong european market germani franc
itali well japan manag note call compani reach
reimburs coverag opdivo major indic almost key market
europ approxim total opdivo sale lung cancer roughli
come rcc
continu believ adjuv neoadjuv therapi becom
import market inhibitor near futur see previou note april
opdivo market share adjuv melanoma current
 bmi ceo giovanni caforio note recent competitor confer adjuv
melanoma repres signific opportun approxim patient
potenti candid treatment adjuv melanoma set
patient popul approxim half treat half patient
treat half treat yervoy past patient
treat histor yervoy sinc approv opdivo adjuv set
rapid declin use yervoy adjuv melanoma set though
believ opdivo well equip make yervoy declin set manag
point call yervoy trend begun stabil compani
outlook yervoy back half year remain posit result continu
leadership opdivo yervoy metastat melanoma launch low dose
yervoy rcc accord rcc-treat patient popul
patient japan popul roughli
doubl size set rcc opdvio current maintain market share
approxim
page analyst certif import disclosur
increas awar tmb
manag note tmb receiv increas interest biomark follow
readout earlier month accord bmi market research awar
tmb emerg biomark nsclc doubl follow
survey includ commun oncologist well academ oncologist
pre-aacr confer note data
subpopul patient includ comparison plu chemotherapi
manag note similar interest tmb intern across thought
leader commun activ work achiev partnership biomark
compani make tmb test wide avail
although continu see tmb potenti import note take
time adopt post-approv opdvio yervoy lung despit increas
bristol-my squibb record revenu billion repres growth yoy
exclud fx impact revenu driven primarili strong opdivo eliqui
growth net revenu yoy intern sale increas yoy
yoy exclud fx impact record net earn non-
gaap ep came respect compani end quarter
cash cash equival market secur billion net cash posit
billion
decreas non- ep guidanc rang
previous previous respect
world-wide sale expect increas yoy mid-singl digit compani
expect effect tax rate non-
made adjust model base perform guidanc
manag commentari morn earn call model global revenu
repres growth yoy estim global revenu
come yoy yoy respect
lower tax rate result updat guidanc provid
morn earn call slowli declin rate subsequ year
adjust non-gaap ep estim come ep estim
decreas base reduct opdivo estim
lung market opdivo estim come
valuat risk
valuat price target base dcf analysi use unchang
wacc lt growth rate maintain buy rate
risk risk rate estim price target includ larger anticip
impact competit pressur hep space impact loe product
reyataz sustiva neg setback clinic pipelin increas
pressur price brand product price debat continu competit
pressur io space
page analyst certif import disclosur
million except per-shar figur
revenu geographi
equiti incom affili
convert debt interest expense/dividend attribut unvest share
compani document guggenheim secur llc estim
page analyst certif import disclosur
